Loading organizations...
§ Private Profile · Jersey City, NJ, USA
Healthcare AI technology company providing AI-driven NLP for clinical research, pharmaceutical development, and real-world evidence generation.
Dyania Health is a Jersey City, New Jersey-based healthcare technology company that utilizes artificial intelligence and natural language processing to automate medical record analysis and streamline clinical trial eligibility screening. The enterprise operates with a team of 21 to 50 employees across the United States and Greece, and it has secured $19.25 million in total capital to develop its proprietary Synapsis AI platform. This software serves clinical research organizations, healthcare systems, and pharmaceutical institutions by matching patients with relevant medical trials and generating real-world evidence for ongoing drug development. The organization maintains institutional affiliations with networks like Endeavor Greece, while its executive leadership and advisory board draw on prior professional and academic experience from Morgan Stanley, Harvard, UCLA, and MIT. Dyania Health was officially founded in 2019 by former investment banker Eirini Schlosser.
Dyania Health has raised $15.0M across 2 funding rounds.
Dyania Health has raised $15.0M in total across 2 funding rounds.
Dyania Health is a healthcare AI company founded in 2019 that builds Synapsis AI, a proprietary large language model (LLM)-based platform automating electronic medical record (EMR) review.[1][2][4] It serves healthcare systems, physicians, pharmaceutical sponsors, and researchers by processing structured and unstructured EMR data in under 0.5 seconds—tasks that take humans 30 minutes or more—with ~95% accuracy, outperforming medical professionals.[1][6][8] The platform solves manual chart review inefficiencies for clinical trial pre-screening, observational studies, registry reporting, therapeutic gap identification, quality of care measurement, and evidence-based care pathways, enabling faster patient matching, precision medicine, and reduced trial timelines.[1][3][7] With 21-50 employees, offices in Jersey City, NJ, and Athens, Greece, and $10M in recent funding, Dyania shows strong growth momentum through partnerships with large healthcare systems and pharma, scaling engineering and AI capabilities.[4][6]
Dyania Health was founded in 2019 by Eirini Schlosser, its CEO, as a female-founded venture addressing manual EMR abstraction challenges.[2][4][6] Schlosser, with a background in healthcare AI development spanning a decade, led the creation of Synapsis AI to handle complex, inconsistent medical data at scale.[2] The idea emerged from recognizing that human review of EMRs—for clinical trials or care optimization—was too slow and error-prone, prompting a computational platform blending natural language processing (NLP), machine learning, and physician input.[5][8] Early traction came via Endeavor Greece selection in 2022, validation from in-house clinicians for LLM training, and deployment in diverse U.S. and global therapeutic areas, including oncology and cardiology.[1][4][8] Pivotal moments include raising $10M to expand AI and partnerships, revolutionizing trial patient matching.[3][6]
Dyania rides the AI-in-healthcare wave, leveraging LLMs for NLP on unstructured EMRs amid exploding data volumes and clinician burnout from manual reviews.[2][4][6] Timing aligns with post-2020 AI advancements and regulatory pushes for faster trials (e.g., FDA emphasis on diversity/recruitment), where 80-90% of trials fail on enrollment delays—Synapsis cuts this by automating matching for hard-to-find patients.[1][3] Market forces like rising pharma R&D costs ($2.6B/trial average), payer demands for evidence-based care, and enterprise AI adoption favor Dyania, influencing the ecosystem by boosting trial efficiency, patient access to therapies, and real-world evidence generation.[6][7] As part of Motivate VC's portfolio and Endeavor-backed, it accelerates AI precision medicine, competing with firms like Iterative Health while expanding to autoimmune, oncology, and cardiology.[1][2][3]
Dyania Health is poised to dominate AI-driven EMR automation, with next steps focusing on engineering scale-up, deeper pharma/health system integrations, and proprietary LLM enhancements for rare diseases and diagnostics.[4][6][8] Trends like multimodal AI, federated learning for privacy, and value-based care will propel growth, potentially capturing share in the $50B+ clinical trial market. Its influence may evolve from trial enabler to enterprise care optimizer, empowering global patient outcomes as AI maturity reduces skepticism. This positions Dyania as a transformative force, directly tackling healthcare's data bottleneck to unlock faster, equitable innovation.[1][7]
Dyania Health has raised $15.0M across 2 funding rounds. Most recently, it raised $10.0M Series A in October 2024.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Oct 25, 2024 | $10M Series A | — | — | Announced |
| Sep 1, 2022 | $5M Seed | — | .406 Ventures, Glasswing Ventures, Innospark Ventures | Announced |
Dyania Health has raised $15.0M in total across 2 funding rounds.
Dyania Health's investors include .406 Ventures, Glasswing Ventures, Innospark Ventures.